(no subject)
Dear all,
Here is a brief update.
EFTA_R1_00043076
EFTA01748145
NASA would like NV to assist with brain monitoring, sleep and alertness, on a 5 day transpacific solar powered flight, in addition to ISS. We are requesting more details re scientific returns and budget;
Talks with Samsung are proceeding fine and they already sent us a doe today which is under legal review. Ironically, on top of our wireless EEG streaming patent, they are most interested in a technology which we initially developed for entirely humanitarian reasons and for which we have not realized a return on, yet. We have asked Samsung to give us an idea of the projected returns should we accept to license this technology to them for a consumer product.
There were fantastic meetings in Silicon Valley, including with a bank interested in bridge financing. There were also a number of very constructive 1-1 meetings with founding managing directors of the top VCs in the healthcare and consumer spaces. I think we could work well with any of them, provided they invest in the same manner as current investors.
The prospectus for the IBRAIN Fund is not ready for show time yet, but is a work in progress. Meetings in Southern California this week.
Talk in LA went well and lead to meeting this evening in LA with a number of prospective investors, including some closely associated to Eli & Edythe Broad, strong backers of neuroscience, including at MIT.
We have received proposal for the first tranche study with the bedding company in partnership with Harvard Medical School's Brigham and Women's Hospital, where I worked in my teens, but we are looking for something a little bolder.
- So there is heightened interest in NV at this time, in terms of investment, from Angels, VCs and Institutional investors, and in terms of partnerships from Academia, Government and Industry. Rather than giving a little to everyone, we need to prioritize our commitments based on our partners' support and expertise. We should take the time to evaluate each prospective partner very carefully, even if this entails accepting some bridge financing. If the consumer aspect takes a life of its own, it is possible it will require significant resources and that the services will not have the same scope as the ones provided to Pharma, with the exception of a companion diagnostic device, in which case it may make sense to separate Pharma, with high margins and lower volume, from the Consumer side, with lower margins and much a higher volume. This would enable value added partners with an allergy to FDA to invest in a consumer product on more familiar terms, without affecting the Pharma work. Of course, the best partners will see the Big Picture, and help us get there faster.
Greetings from La Jolla,
Philip
EFTA_R1_00043077
EFTA01748146
Philip Low, PhD
NeuroVigil, Inc.
Founder Chairman & C.E.O.
EFTA_R1_00043078
EFTA01748147
Do you know this company? Howard Morgan involved. I wanted to invest at the beginning but not possible. Phillip is brilliant.
iPhone feature: Tupos & Abbrvtns
Begin forwarded message:
This image is not a chart. It appears to be an email header.
Key Information:
- Sender: Philip Low
- Date: October 6, 2014, 2:48:11 PM PDT
- Recipients (To): Monte Stettin, Howard Morgan
- Recipients (Cc): Don Spencer, Irwin Jacobs, "Sejnowski, Terry", "Draper, Timothy", Brook Byers, Peter Farrell, Naveen Jain, "Mittendorff, Robert", "Landreth, Riley", "Sarkar, Molly", "Jacobs, Paul", Yasemin Denari, "Flint, Alexis", Reena Horowitz, Jack White, "Ancoli-Israel, Sonia", "Dyson, Esther", Michael Herf, Jacqueline Monash, "Kraft, Daniel", Graham, Ron, "Spire, Jean-Paul", Andrew Viterbi, "Winter, Philippe", "Horowitt, Greg", Roger Guillemin, "Chester, Linda", "Rind, Kennet", Anita Hovanissian, Andy Pelletier, Michael McCullough, Sam Horowitz, Judy White, Paul Kreutz, ggaspen, Stephen Wolfram, Michael Farrell, Jay Kranzler, Emily Polidan, Stanley Barton, ronald graham
- Subject: Update
Dear all,
Here is a brief update.
EFTA_R1_00043076
EFTA01748145
NASA would like NV to assist with brain monitoring, sleep and alertness, on a 5 day transpacific solar powered flight, in addition to ISS. We are requesting more details re scientific returns and budget;
Talks with Samsung are proceeding fine and they already sent us a doe today which is under legal review. Ironically, on top of our wireless EEG streaming patent, they are most interested in a technology which we initially developed for entirely humanitarian reasons and for which we have not realized a return on, yet. We have asked Samsung to give us an idea of the projected returns should we accept to license this technology to them for a consumer product.
There were fantastic meetings in Silicon Valley, including with a bank interested in bridge financing. There were also a number of very constructive 1-1 meetings with founding managing directors of the top VCs in the healthcare and consumer spaces. I think we could work well with any of them, provided they invest in the same manner as current investors.
The prospectus for the IBRAIN Fund is not ready for show time yet, but is a work in progress. Meetings in Southern California this week.
Talk in LA went well and lead to meeting this evening in LA with a number of prospective investors, including some closely associated to Eli & Edythe Broad, strong backers of neuroscience, including at MIT.
We have received proposal for the first tranche study with the bedding company in partnership with Harvard Medical School's Brigham and Women's Hospital, where I worked in my teens, but we are looking for something a little bolder.
- So there is heightened interest in NV at this time, in terms of investment, from Angels, VCs and Institutional investors, and in terms of partnerships from Academia, Government and Industry. Rather than giving a little to everyone, we need to prioritize our commitments based on our partners' support and expertise. We should take the time to evaluate each prospective partner very carefully, even if this entails accepting some bridge financing. If the consumer aspect takes a life of its own, it is possible it will require significant resources and that the services will not have the same scope as the ones provided to Pharma, with the exception of a companion diagnostic device, in which case it may make sense to separate Pharma, with high margins and lower volume, from the Consumer side, with lower margins and much a higher volume. This would enable value added partners with an allergy to FDA to invest in a consumer product on more familiar terms, without affecting the Pharma work. Of course, the best partners will see the Big Picture, and help us get there faster.
Greetings from La Jolla,
Philip
EFTA_R1_00043077
EFTA01748146
Philip Low, PhD
NeuroVigil, Inc.
Founder Chairman & C.E.O.
EFTA_R1_00043078
EFTA01748147